Fiche centre
Rigshospitalet
Copenhagen — Denmark
Essais liés17clinical trials
VilleCopenhagenlocalisation
PaysDenmarklocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06757634
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| MyoSense 360 | Myasthénie | Non applicable | NCT07323316 | HARMONY 360 — Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360 | RECRUITING |
| PVI Ablation | Maladie coronarienne | Non applicable | NCT07523620 | CLEAR — Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration | RECRUITING |
| Tociliuzumab | Accident vasculaire cérébral | Phase 2/3 | NCT07870681 | Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE | NOT_YET_RECRUITING |
| Percutaneous transluminal angioplasty (PTA) | Insuffisance cardiaque | À vérifier | NCT07531966 | DAN-PTRAIII — Vascular Complications After Kidney Transplantation | RECRUITING |
| Arm A: Gedatolisib + Palbociclib + Fulvestrant | Cancer | Phase 3 | NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | RECRUITING |
| Cyclophosphamide and ATG | SEP | Phase 3 | NCT03477500 | Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) | ACTIVE_NOT_RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| Inotuzumab ozogamicin | Cancer | Phase 2 | NCT05748171 | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| Nipocalimab | Lupus | Phase 3 | NCT07438496 | GARDENIA-SLE — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | RECRUITING |
| Physical Activity and Fatigue in Myasthenia Gravis | Myasthénie | À vérifier | NCT03905473 | Physical Activity and Fatigue in Myasthenia Gravis | COMPLETED |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |